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Radiation-induced synthetic lethality: combination of poly(ADP-ribose)
polymerase and RAD51 inhibitors to sensitize cells to proton irradiation
Anne-Catherine Wéraa, Alison Lobbensa, Miroslav Stoyanov a, Stéphane Lucasb, and Carine Michiels a
aURBC-NARILIS, University of Namur, Namur, Belgium; bLARN-NARILIS, University of Namur, Namur, Belgium
ABSTRACT
Although improvements in radiation therapy were made over the years, radioresistance is still
a major challenge. Cancer cells are often deficient for DNA repair response, a feature that is
currently exploited as a new anti-cancer strategy. In this context, combination of inhibitors
targeting complementary pathways is of interest to sensitize cells to radiation. In this work, we
used PARP (Olaparib) and RAD51 (B02) inhibitors to radiosensitize cancer cells to proton and X-ray
radiation. More particularly, Olaparib and B02 were used at concentration leading to limited
cytotoxic (alone or in combination) but increasing cell death when the cells were irradiated. We
showed that, although at limited concentration, Olaparib and B02 were able to radiosensitize
different cancer cell lines, i.e. lung and pancreatic cancer cells. Antagonistic, additive or synergistic
effects were observed and correlated to cell proliferation rate. The inhibitors enhanced persistent
DNA damage, delayed apoptosis, prolonged cell cycle arrest and senescence upon irradiation.
These results demonstrated that radiation-induced synthetic lethality might widen the therapeutic
window, hence extending the use of PARP inhibitors to patients without BRCAness.
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1. Introduction
During the course of their treatment, about 50%
of cancer patients will undergo radiotherapy [1].
Although improvements were made over the last dec-
ades to optimize the therapeutic index, radioresistance
remains a concern and two major strategies are envi-
saged by Baumann et al. to improve patient outcome
[2–4]: improvement of radiation dose conformity and
biological strategies to optimize cell response.
In the seeking of the optimal dose spatial distribu-
tion, the emerging use of high energy charged particles
like protons or carbon ions are major advances [5,6].
The advantage of heavy-charged particles compared
to photons is the Bragg peak, i.e. the significant
increase in the depth dose profile at the end of the
particle track allowing dose depositionwith high accu-
racy and sparing of surrounding healthy tissues.
Regarding biological strategies, synthetic lethality is
proposed to optimize cancer cell response to radiation
with the idea of exploiting the addiction of cancer cells
to DNA repair. A successful example is the use of
a poly(ADP-ribose) polymerase (PARP) inhibitor
(PARPi) on tumor with breast cancer susceptibility 1
and 2 (BRCA1/2) mutations [7,8]. PARP is rapidly
activated upon DNA damage and, in response, binds
to induced single-strand breaks (SSBs). SSBs can be
generated by ionizing radiation or induced by the base
excision repair (BER) pathway after exposure to alky-
lating agent like temozolomide. PARP uses nicotina-
mide adenine dinucleotide (NAD+) as a substrate
generating nicotinamide and ADP-ribose, eventually
forming long branched poly(ADP-ribose) chains
which recruit the BER proteins. The use of PARPi
leads to the stabilization of these SSBs which are
translated into double-strand breaks (DSBs) at the
replication fork. These DSBs, produced during
S phase, are repaired through the homologous recom-
bination (HR) pathway in which BRCA1 and BRCA2
are key proteins, but, when the cells are BRCA1/2
deficient, these DSBs are not repaired and can lead
to cell death. Although the treatment of BRCA1/2
mutated patients with PARPi is giving promising
results, resistance to treatment has been reported
[9,10]. Examples of identified resistance mechanisms
are secondary mutations in BRCA genes restoring the
open reading frame of BRCA2 [11] and overexpres-
sion of RAD51 partially overcoming the initial HR
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defect [12]. RAD51 is one of the key proteins of the
HR pathway promoting the DNA strand exchange
after searching for the homolog sequence. RAD51
mRNA and protein levels are higher in cancer cells
than in normal cells. Therefore, RAD51 is now con-
sidered as a clinically relevant target for combined
therapies [10]. Small molecules have been developed
to target RAD51, some lead to inhibition of RAD51-
ssDNA nucleoprotein filament formation but others
can also inhibit the D-loop formation [13]. RAD51
inhibitors, like B02, lead to an inhibition of HR and
sensitize cells to DSBs [14–18].
In our work, we propose to take advantage of the
combination of PARP and RAD51 inhibitors,
Olaparib (AZD2281) and B02, respectively. This strat-
egy seems very promising not only to counteract the
resistance associated with PARPi but also to extend
theuse of PARPi to patientswithoutBRCAmutations.
More particularly, we worked in the frame of radia-
tion-induced synthetic lethality, i.e. we used PARPi
and RAD51i at concentrations that led to limited
cytotoxic (alone or in combination) but to an
increased cell death when the cells were irradiated
with protons or X-rays.
2. Material and methods
2.1. Cell culture and inhibitors
Human A549 non-small-cell lung cancer (NSCLC)
cells were sub-cultured in Glutamax Modified
Eagle’s Medium (Gibco Life Technologies) supple-
mented with 10% fetal bovine serum (FBS) (Gibco).
KP4 and PANC1 pancreatic cancer cells were sub-
cultured in 4500 mg/l glucose Dulbecco’s Modified
Eagle’s Medium (Gibco Life Technologies) 10% FBS
supplemented. For the experiment, the medium was
supplemented with 0.5% penicillin/streptomycin
(Sigma). Olaparib (AZD2281, S1060, Selleckchem),
a poly(ADP-ribose) polymerase inhibitor, was used
at 0.5 µM final concentration. B02 (Millipore),
a RAD51 inhibitor, was used at 10 µM final concen-
tration. Cells were incubated in the presence of the
inhibitors for a total duration of 24 h.
2.2. Proton and x-ray irradiation
The experimental set-up and irradiation procedure
for protons using a 2MV tandem accelerator are
described in [19,20]. The proton beam energy was
set to 1.3 MeV corresponding to a fixed linear
energy transfer (LET) of 25 keV/µm within the
cell monolayer. This LET is the one leading to
the highest effect of protons in cells [21] and is
found at the end of each particles track composing
the spread out Bragg peak found in clinic. The
dose-rate was set to 2 Gy/min.
For X-ray irradiation, cells were seeded at the same
density as for the proton irradiation (800 cells/µl)
the day before the irradiation. Irradiations were per-
formed at 225 kV (X-RAD225-XL, PXI) and the dose-
rate set to 2 Gy/min.
For proton and X-ray irradiation, 3 to 4 h before
irradiation, the culture medium was replaced with
medium containing: no inhibitor (No Inh.); 0.5 µM
Olaparib (Ola.); 10 µM B02 (B02) or 10 µM B02 and
0.5 µM Olaparib (B + O). The medium was supple-
mented or not with 10% FBS.
2.3. Immunofluorescence labeling
Experiment was performed following the proce-
dure described in [22]. The primary antibodies
used were: rabbit polyclonal antibody anti-RAD
51 antibody (HPA039310, Sigma), mouse mono-
clonal anti-pADPr antibody (ab14459, Abcam)
and rabbit anti-phospho-histone H2AX (9664,
Cell Signaling). Primary antibodies were diluted
at 1:400 in bovine serum albumin (BSA) 2% in
phosphate buffer saline (PBS). Secondary antibo-
dies used were Alexa 488 nm anti-rabbit antibody
(Fisher Scientific) and Alexa 568 nm anti-mouse
antibody (Fisher Scientific) diluted at 1:1000 in
PBS-BSA 2%. Nuclei were stained with 2.5 mg/ml
DAPI (Sigma). The observations were performed
by confocal microscopy by keeping the photomul-
tiplier at a constant gain (Leica SP5).
2.4. Colony forming assay and survival fraction
After the irradiation, cells were detached using
trypsin, then counted and seeded in six-well plates
at desired concentrations in medium supplemen-
ted with 10% FBS containing the inhibitors. More
precision on the procedure can be found in
[19,20]. After 24 h, the medium was refreshed
with FBS-supplemented medium without inhibi-
tors and cells were left to proliferate. Twelve days
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post irradiation, the number of visible colonies
(containing more than 50 cells) was counted after
staining with crystal violet in 2% ethanol. At least
three independent experiments were performed,
and data are presented as mean ± 1 SD.
Experimental data were fitted with the linear-
quadratic model (LQ) using GraphPad Prism 5.0
(GraphPad Software) given by the formula:
SF ¼ e αDβD2ð Þ
where SF is the surviving fraction, α (Gy−1) and β
(Gy−2) are the radiosensitivity parameters and D is
the dose. The method used was least square regres-
sion line with data weighted with 1/SD2.
From the survival fraction data, the Sensitivity
Enhancement Ratio (SER) is obtained as:
SER ¼ D50Nodrug
D50Drug
where D50 is the dose required to reach 50%
survival.
Finally, whenworking with drugs, the coefficient of
drug interaction (CDI) highlights the potentiation
obtained when combining two of them. Based on the
survival fraction curves, the CDI was calculated as
follows:
CDI ¼ SFDBþO
SFDOla:  SFDB02 
1
SFD
where SFD is the survival fraction associated to
a dose D in the case of no inhibitor (SFD), Olaparib
(SFD-Ola.), B02 (SFD-B02) and the combination
Olaparib + B02 (SFD-B+O).
2.5. Flow cytometry
After the irradiation, cells were detached using
trypsin, then counted and seeded in six-well plates.
24, 48 and 72 h after irradiation, cells were trypsi-
nized, rinsed with PBS. For cell cycle arrest, cells
were fixed/permeabilized in 70% ethanol and kept
at −20°C before incubation with 50 µg/ml RNAse
for 15 min at 37°C staining with 10µg/ml propi-
dium iodide (Sigma). For apoptosis assessment,
a FITC Annexin V detection kit was used (BD
Pharmignen, #556547). Analysis was performed
using FACS Verse (BD Biosciences). Cell-cycle dis-
tributions were determined using ModFit. At least
three independent experiments were performed,
and data are presented as mean ± 1 SD.
2.6. Senescence-associated beta-galactosidase
After the irradiation, cells were detached using
trypsin, then counted and seeded in six-well plates.
Seven days after irradiation, A549 cells were fixed
with 2% formaldehyde, 0.2% glutaraldehyde in
PBS for 5 min. Cells were rinsed twice with PBS
and incubated at 37°C for 16 h in the staining
solution containing: x-gal (20 mg/ml) (#0428-1G,
Amresco), phosphate buffer (pH 6), potassium
ferricyanide (100 mM), potassium ferrocyanide
(100 mM), NaCl (2.5 M) and MgCl2 (1 M). After
incubation, cells were rinsed twice with PBS and
twice with methanol before observation under
optical microscope [23].
3. Results
3.1. Determination of Olaparib and B02
concentration resulting in limited cytotoxicity
To work in the frame of radiation-induced synthetic
lethality, non-toxic concentrations of the inhibitors
were chosen. Clonogenic assays were used to evalu-
ate this cytotoxicity. Concentrations equal to 0.5 µM
for Olaparib and to 10 µM for B02 led to a limited
toxicity alone and in combination (Figure1(a-b))
and were chosen for this work. We then verified
that these concentrations exert an inhibitory effect
on their respective targets. Cells were treated with 1
µM bleomycin for 2 h to produce SSBs and PARP
inhibition by Olaparib was evaluated by poly(ADP-
ribose) (pADPr) chain immuno-labeling (Figure 1
(c)). Similarly, RAD51 inhibition by B02 was mea-
sured on cells irradiated with 2 Gy X-ray and labeled
for RAD51 3 h later (Figure 1(d)). Results showed
a significant decrease in the target after treatment at
the chosen concentration. The level of pADPr and
RAD51 foci formation was also evaluated 3 h and 24
h after 2 Gy proton irradiation. Reduced levels of
targets were observed when A549 cells were incu-
bated with Olaparib or B02 (supplementary Figures
S1-S2). Altogether, these results show that 0.5 µM
Olaparib and 10 µM B02 allowed a significant inhi-
bition of the respective targets.
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3.2. Olaparib and B02 induce changes in DSB
induction and repair after proton irradiation
In order to highlight the effect of the inhibitors on
the DSB repair kinetics, A549 cells were irradiated
with 2 Gy protons and labeled for phospho-H2AX
(γH2AX) 30 min, 2 h and 24 h postirradiation
(Figure 2(a)) and quantify (Figure 2(b–d)). After
30 min and 2 h, a significant increase in the
number of foci per cell was observed in cells irra-
diated with 2 Gy compared to non-irradiated cells,
with or without inhibitors. At 24 h, there was no
longer a difference between irradiated and non-
irradiated cells incubated in the absence of inhibi-
tor, indicating DSB repair. However, if the cells
were incubated in the presence of the inhibitors,
the number of scored γH2AX foci was still signifi-
cantly higher compared to non-irradiated cells. At
24 h, the number of foci recorded for cells irra-
diated with B02 (with or without Olaparib) was
significantly higher compared to cells irradiated
without inhibitor (Figure2(b)).
Based on the number of foci scored, the propor-
tion of γH2AX positive cells presenting more than
eight foci (Figure 2(c)) and the mean number of
foci per cell (Figure 2(d)) were determined. Along
post-irradiation time, γH2AX level decreased,
indicating DSB repair. However, the proportion
of positive cells at 24 h increased from 5% (0.8



















































































Figure 1. Inhibitor cytotoxicity and efficiency. (a-b) A549 cells were exposed to increasing concentrations of Olaparib and B02 during
24 h. The survival fraction was determined using clonogenic assays 12 days after treatment. (a) Survival fraction obtained after
exposure to Olaparib; (b) Survival fraction obtained after exposure to B02. Three independent experiments were performed, and data
are presented as mean ± 1 SD. The data have been adjusted to a sigmoidal dose–response curve using GraphPad Prism. (c-d)
Inhibitor efficiency at the chosen concentration: 3 h before exposure, A549 cells were incubated in the presence or absence of 0.5
µM Olaparib (Ola.), 10 µM B02 (B02) or the two inhibitors (B+O). (c) After a 2 h exposure to 1 µM bleomycin, A549 cells were labeled
for pADPr and the proportion of pADPr positive cells determined; (d) 3 h after 2 Gy X-ray irradiation, A549 cells were labeled for
RAD51 and cells with more than 5 RAD51 foci scored. Three independent experiments were performed, and data are presented as
mean ± 1 SD. Mann-Whitney statistical analyses were performed (p > 0.05: ns; p < 0.05: *; p < 0.01: **; p < 0.001: ***).
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foci/cell) in the absence of inhibitor, 7% (1.5 foci/
cell) for Olaparib, 10% (2.2 foci/cell) for B02 to
15% (3.3 foci/cell) for cells incubated with
Olaparib and B02.
3.3. Olaparib and B02 enhance proton
irradiation-induced cell cycle arrest
To determine the influence of the inhibitors and
their combination on cell response after irradiation
protein and mRNA extraction were performed 24
h post-irradiation. The results (Figure S3A-D)
showed an increased abundance of p21 at protein
and mRNA level, especially with inhibitor combina-
tion as well as a decreased level of Ki67. Based on
these observations, cell cycle arrest was determined
by flow cytometry 24, 48 and 72 h after 2 Gy proton
irradiation in the presence or absence of inhibitors
(Figure 3(a-b)). Early and late apoptosis assessment
was also performed at the same time point post-
irradiation (Figure 3(c-d)). In accordance with the
results from the protein and mRNA analysis, B02
combined or not to Olaparib led to a decreased











































































































































































30 min 2 h 24 h
Figure 2. Olaparib and B02 induced changes in DSB repair. A549 cells were irradiated with 2 Gy protons. 3 to 4 h before irradiation,
cells were incubated in the presence or absence of 0.5 µM Olaparib (Ola.), 10 µM B02 (B02) or the two inhibitors (B+O). 30 min, 2
h and 24 h after irradiation, cells were labeled for γ-H2AX. (a) Representative images; (b) Number of foci per cell counted on one
focal plane 30 min, 2 h and 24 h after irradiation. One way ANOVA (Tukey) statistical analyses were performed (p > 0.05: ns; p < 0.05:
*; p < 0.01: **; p < 0.001: ***); (c) Proportion of cells with more than 8 foci 30 min, 2 h and 24 h after 2 Gy irradiation; (d) Mean
number of foci (Mean & SEM) after 2 Gy irradiation at 30 min, 2 h and 24 h. Data from two independent experiments (more than 100
cells per sample were counted).
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irradiated cells. This was no longer observed at later
time points. As highlighted in Figure3(b), proton
irradiation induced a massive G2 cell cycle arrest
24 h after irradiation for cells incubated or not with
inhibitors. Without inhibitor, G0/G1 level was back
to the control level from 48 h after irradiation while
S phase level was still low. For cells incubated with
inhibitors, the proportion of G1 cells was still lower
than respective controls 48 h after irradiation, espe-
cially in the case of cells incubated with B02 com-
bined or not to Olaparib. No recovery of cells
arrested in G2 phase was observed 72 h after irradia-
tion for cells incubated with B02 and Olaparib while
it reduced from 55% to 39% in cells irradiated with-
out inhibitors and from 61% to 46% in cells incu-





Figure 3. Inhibitors effects on cell cycle arrest and apoptosis. A549 cells were irradiated with 2 Gy protons. 3 to 4 h before
irradiation, cells were incubated in the presence or absence of 0.5 µM Olaparib (Ola.), 10 µM B02 (B02) or the two inhibitors (B + O).
(a) Representative spectrum of flow cytometry analysis for cell cycle arrest obtained 72 h after irradiation; (b) Proportion of cells in
G0/G1, S and G2 24 h, 48 h and 72 h after irradiation; (c) Representative spectrum of flow cytometry analysis of apoptosis obtained
72 h after irradiation; (d) Proportion of apoptotic (Annexin-V positive) cells. Three independent experiments were performed, and
data are presented as mean ± 1 SD.
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15% of apoptotic cells 24 h after irradiation indicat-
ing limited apoptosis but this proportion increased
over post-irradiation time leading to a cumulative
proportion of apoptotic cells around 40% in the
absence of inhibitor to more than 50% in cells
exposed to both inhibitors.
3.4. Proton-irradiation induces delayed cell
death
After irradiation, cells that did not form colonies, but
that were still attached to the dish were observed.
Since massive cell cycle arrest and increased levels of
p21 protein andmRNA were observed, we evaluated
if proton irradiation-induced senescence. For that



































































































Figure 4. Delayed cell death. A549 cells were irradiated with 2 Gy protons. 3 to 4 h before irradiation, cells were incubated in the
presence or absence of 0.5 µM Olaparib (Ola.), 10 µM B02 (B02) or the two inhibitors (B+O). Seven days after irradiation A549 cells
were stained for beta-galactosidase to detect senescent cells or with DAPI to visualize cell nuclei. (a–d): Colonies with more than four
cells were recorded and scored as positive if they contained one or more blue cells. (a) Senescent cell outside of a colony, not
recorded; (b) Colonies without senescent cells, recorded as negative; (c) Colonies with one or more senescent cells, recorded as
positive; (d) Quantification β-gal positive colonies for cells irradiated with protons. Mann-Whitney statistical analyses were
performed. Data based on two independent experiments each with 2 replicates (more than 50 colonies counted for each replicate).
(e) Nuclei stained with DAPI 7 days after 2 Gy proton irradiation showing nuclei with normal shape or abnormal shape (enlarged,
apoptotic, micronuclei, multinucleated); (f) Nuclei were counted within colonies or single cells and cells with micronuclei, giant
nuclei, multinuclei or apoptotic nuclei scored. Data from three independent experiments.
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stained for beta-galactosidase (β-gal) under acidic
pH allowing to detect senescent cells. Examples are
presented in Figure 4. Among the cell population,
different features were observed: β-gal positive cells
outside of a colony of less than four cells (Figure 4
(a)), these cells were not recorded for the quantifica-
tion; colonies without any β-gal positive cells (Figure
4(b)), these colonies were recorded as negative; colo-
nies containing one or more β-gal positive cells
(Figure 4(c)), these colonies were recorded as posi-
tive colonies. All cells found in non-irradiated con-
dition formed colonies and about 10% to 20% of
these colonies were positive for β-gal. After 2 Gy
proton irradiation, a large number of cells that did
not produce clones and that exhibited a positive
staining were observed. For the cells that generated
colonies, the proportion of positive colonies was
significantly higher for irradiated cells compared to
non-irradiated cells (40% to 50%) (Figure 4(d)).
In parallel, cells were labeled with DAPI (Figure 4
(e-f)) allowing to detect cells undergoing apoptosis or
cells with abnormal nucleus like giant nucleus, multi-
nucleated cells or presenting micronuclei. In non-
irradiated cells, incubated or not with Olaparib and
B02, all cells were found in colonies and about 10–15%
of the cells presented an abnormal shape (multinu-
cleated for ~80% of them). After 2 Gy proton irradia-
tion, cells were found amongst colonies as well as
single cells staying attached to the coverslip.
Amongst the colonies, 25% of the cells presented an
abnormal shape with a majority of them being multi-
nucleated (~60%), presenting micronuclei (~25–30%)
or having an enlarged nucleus (~10%). In the cells that
did not form colonies after irradiation, 70% of them
displayed an abnormal shapewith a higher proportion
of micronuclei (55%), enlarged nuclei (20%) or even
apoptotic bodies (10%). Although a clear effect of the
irradiation was obtained, no difference was detected
between cells incubated with or without Olaparib
and B02.
3.5. Olaparib and B02 radiosensitize cells to
protons and x-rays
To evaluate the radiosensitizing potential of the
inhibitors and of their combination, A549 cell
survival fraction curves were determined after
exposure to increasing doses of protons or
X-rays. To detect the effect of the inhibitors, 3 to
4 h before irradiation the cells were incubated in
medium with serum and containing or not the
inhibitors. The cells were incubated in the pre-
sence of inhibitors during 24 h then the medium
was refreshed. For each inhibitor, the survival frac-
tion was determined 12 days post-irradiation in
comparison to the respective controls.

















Figure 5. Survival fraction. A549 cells were exposed to 225 kV X-rays or 25 keV/µm broad proton beam at 2 Gy/min. 3 to 4 h before
irradiation, cells were incubated in medium with serum containing or not the inhibitors, i.e. no inhibitor, 0.5 µM Olaparib, 10 µM B02
and B02+ Olaparib. The survival fraction was determined using clonogenic assays. Cells were incubated for a total duration of 24
h with: No Inhibitor (black dot); 0.5µM Olaparib (red square); 10 µM B02 (blue up triangle), 10 µM B02 0.5 µM + Olaparib (green
down triangle) then in control culture medium for 11 days. At least three independent experiments were performed, and data are
presented as mean ± 1 SD. The data have been fitted using the Linear-Quadratic model for X-rays (filled symbols and lines) and
Linear model for protons (empty symbols and dotted lines).
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A549 cell survival fractions obtained after X-ray
and proton irradiation are presented in Figure 5.
The results showed shouldered survival fractions
after X-ray irradiation while a linear trend was
obtained after proton irradiation with
a significantly lower survival compared to X-rays.
For the two types of radiation, radiosensitization
was observed in the presence of the inhibitors.
The data were adjusted to the Linear-Quadratic
(X-rays) or Linear (protons) model. For both
radiation types, the results showed
a radiosensitization when using Olaparib and/or
B02 with SER between 1.14 and 1.27 and a further
enhancement if the inhibitors were combined with
SER up to 1.46 associated to a decreasing survival
at 2 Gy (Table 1).
3.6. Combined effect of Olaparib and B02 after
proton irradiation depends on proliferation rate
The survival fraction after proton irradiation was
also determined for A549 cells irradiated in med-
ium without serum (Figure 6, top panel) and the
coefficient of drug interaction calculated. CDI is
used to highlight an antagonist (CDI >1), additive
(CDI = 1) or synergistic (CDI <1) effect between
two drugs. For cells irradiated in the presence of
serum, CDI decreased with dose and ranged from
0.98 (0.5 Gy) to 0.89 (3 Gy) indicating an additive
effect of the combination of Olaparib and B02 or
even a slight synergy at higher doses. This synergy
was no longer observed if cells were irradiated in
medium without serum, the inhibitor combina-
tion led to an antagonist effect with CDI of 1.17
at 2 Gy. Indeed, although a radiosensitization was
observed (SER≈1.20), the combination of inhibi-
tors did not further decrease the survival fraction.
To explain this marked effect of serum regarding
the radiosensitization effect of the inhibitors, the
proportion of proliferating cells at the irradiation
time was assessed using pulsed BrdU incorpora-
tion. For that purpose, cells were handled in the
exact same way as for irradiation and BrdU was
added for 45 min before the irradiation time. Flow
cytometry analysis allowed to determine the pro-
liferating cell proportion but also to highlight dif-
ferences in the rate of BrdU incorporation. The
analysis showed a 40% BrdU positive population
in all treatments, but a higher incorporation of
BrdU in the cells incubated with serum. This
indicates that the proliferating cells replicated
DNA faster in the presence of serum (Figure S4).
This can explain the higher effect of proton irra-
diation in the presence of the inhibitors when cells
were incubated in medium with serum.
To highlight further that the proliferation rate
influences the drug combination effect after proton
irradiation, cells with different doubling time were
irradiated. For that purpose, pancreatic cancer cells
KP4 and PANC1 (17 and 32 h doubling time,
respectively) were irradiated in the presence of the
same inhibitors combination as A549 cells (dou-
bling time equal to 22 h). As shown in Figure 6
(bottom panel), Olaparib and B02 radiosensitized
pancreatic cancer cells with SER at 37% survival
ranging from 1.3 (Ola. and B02) to 1.8 (B + O) for
KP4, and from 1.3 (B02) to 1.6 (Ola.) for PANC1.
However, the combination of the inhibitors only
sensitized further KP4 cells to proton irradiation.
Indeed, the combination of Olaparib and B02 led
to a synergistic effect (CDI equal to 0.89, 0.79 at 0.5
and 1 Gy) in KP4 cells while for PANC1, displaying
a reduced growth rate, the combination led to an
increasing antagonist effect with dose (CDI equal to
1.41 and 1.99 at 0.5 and 1 Gy).
Altogether, these results showed that antagonist
and additive/synergistic effect could be obtained
with the same drug concentrations after proton
irradiation, depending on the cell proliferation
rate.
Table 1. Radiosensitivity parameters, sensitivity enhancement ratio (SER) and survival fraction at 2 Gy of A549 cells irradiated with
X-rays or protons in the presence or absence of inhibitors in medium with serum.
225 kV X-rays 25 keV/µm protons
α (Gy−1) β (Gy−2) SER SF2Gy α (Gy
−1) SER SF2Gy
No Inh. 0.173 ± 0.066 0.074± 0.002 0.53 1.238 ± 0.052 0.084
Olaparib 0.163 ± 0.004 0.136 ± 0.001 1.21 ± 0.27 0.42 1.569 ± 0.033 1.27 ± 0.08 0.043
B02 0.234 ± 0.084 0.084 ± 0.022 1.17 ± 0.52 0.45 1.417 ± 0.018 1.14 ± 0.06 0.059
B02 + Ola. 0.313 ± 0.012 0.116 ± 0.003 1.46 ± 0.35 0.34 1.786 ± 0.054 1.44 ± 0.10 0.028
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4. Discussion and conclusion
In this work, we proposed to take advantage of the
combination of PARP and RAD51 inhibitors,
Olaparib (AZD2281) and B02 used at a non-toxic
concentration, to sensitize cancer cells to proton
and X-ray irradiation. PARPi have been used in
cell lines without BRCA mutations and showed
synergy with DNA damaging agents, like che-
motherapeutic drugs [24–26], or radiation
[27,28]. For cells possessing efficient DNA repair
machinery, the use of inhibitors impairing com-
plementary pathways like PARPi and RAD51i
seems very promising to increase cell death upon
irradiation.
The cellular responses associated with the use of
the inhibitors in non-irradiated cells were first
studied and, as explained, we aimed for a limited
toxicity. Compared to cells incubated without
inhibitors, increased p21 abundance at protein
and mRNA levels and decreased proportion of
S-phase cells were observed leading to a higher
proportion of β-gal positive cells. This can explain
the decrease of 20% in clonogenic survival for cells
incubated with both inhibitors. This toxicity is
probably linked to replication stress. Indeed,
RAD51 binds to ssDNA in order to prevent
nucleolytic degradation and this protection is
impaired in presence of B02 [29]. Moreover,
a study reported the induction of cellular senes-
cence by transcriptional repression of DNA repair
genes, like RAD51, in an amplifying loop involving
p53/p21/RB factors [30].
Our results showed that proton irradiation led to
an increased p53 protein level. p53 activates
a plethora of cellular responses including the initia-
tion of apoptosis and cell cycle arrest. We detected
apoptosis by flow cytometry in only 15% of cells 24



















































Figure 6. Survival fraction. A549, KP4 and PANC1 cells were exposed to 225 kV X-rays or 25 keV/µm broad proton beam at 2 Gy/min.
3 to 4 h before irradiation the cells were incubated in medium without serum (A549) or with serum (A549, KP4, PANC1). The survival
fraction was determined using clonogenic assays. Cells were incubated for a total duration of 24 h with: No Inhibitor (black dot);
0.5µM Olaparib (red square); 10 µM B02 (blue up triangle), 10 µM B02 0.5 µM + Olaparib (green down triangle) then in control
culture medium for 11 days. At least three independent experiments were performed, and data are presented as mean ± 1 SD. The
data have been fitted using Linear model. One way ANOVA (Kruskal–Wallis) statistical analyses were performed (p > 0.05: ns; p <
0.05: *; p < 0.01: **; p < 0.001: ***).
CELL CYCLE 1779
h after irradiation. This lack of apoptosis is not sur-
prising as mitotic catastrophe, resulting from aber-
rant mitosis, is considered as the main cell death
induced by ionizing radiation leading to the forma-
tion of large non-viable cells presenting micronuclei
or multiple nuclei [31–33]. Cells undergoing mitotic
catastrophe can survive days to eventually die by
delayed apoptosis, necrosis or induced senescence.
In previous works, we have shown that A549 cells
irradiated with X-rays, protons or alpha particles
preferentially undergo mitotic catastrophe with
a limited proportion of cells undergoing apoptosis
[20,34]. A small proportion of apoptotic cells was
observed at different time post-irradiation and,
although limited, the observed cumulative effect
could account for the decrease in cell survival. In
parallel, we observed increased p21 mRNA and pro-
tein levels after irradiation. p21 is an inhibitor of
cyclin-dependent-kinases and its induction by p53
leads to cell cycle arrest in G1 due to the inhibition
of CDK4 and CDK6 while it also prevents G2/M
transition initiated by CDK1-cyclinB complex. In
this work, we showed that 2 Gy proton irradiation
led to a massive cell cycle arrest in G2 phase that
persisted 72 h after irradiation. Beside transient cell
cycle arrest, p21 activation has also been identified as
a first step leading to accelerated senescence or stress-
induced premature senescence [35]. This can occur
through CDK2 inhibition and ultimately leads to
radiation-induced senescence [36]. For example,
Wouters et al. exposed p53 wild type HTC116
human carcinoma cells (p21+/+) and a derivative
p21−/- to 10 Gy γ-rays and reported a significantly
lower proportion of apoptotic cells with p21+/+ com-
pared to p21−/- derivative. Although the survival frac-
tion highlighted only a small protection associated to
p21 knockout, the authors reported that the p21+/+
petri dishes contained a “lawn” of attached clono-
genically dead cells while p21−/- did not [37]. It is well
accepted that radiation can lead to senescence and
some studies focus now on the possible recovery or
escape from this senescent state leading to resistance
to treatment [38–41]. We observed that 50% of
recorded colonies 7 days after proton irradiation
contained senescent cells. Moreover, cells that did
not produce clones displayed β-gal activity and, for
the majority of them, were multinucleated, presented
micronuclei or were enlarged. To detect any resur-
gence of those cells, single cell irradiated with 2 Gy
protons were seeded and followed for about two
months. Cells which did not produce colonies after
7 days never recovered, indicating that the senescence
state observed was permanent, at least for isolated
cells. These senescent cells are clonogenically dead
but metabolically active and may be associated with
possible benefit (immune cell attraction) or liability
(promotion of cell proliferation and invasion) for
tumor progression [42–44]. In this research, although
the use of Olaparib and B02 led to increased cell
death that could be associated to accumulation of
apoptotic cells, it did not clear this senescent popula-
tion, suggesting that a focus on the use of adjuvant
senolytic drugs could be an interesting approach to
improve radiation therapy.
We have shown that Olaparib and B02 radiosensi-
tized A549 cells to protons and X-rays with SER up to
1.45. Although the SERwere comparable, the survival
fraction obtained after proton irradiation was as
much as 10 times lower than the ones obtained with
X-rays at 2 Gy when using the inhibitors alone or in
combination. This was expected as the proton energy
used in this work corresponds to the LET leading the
highest effects of protons on cell survival. Twenty-
four hours after 2 Gy proton irradiation, analysis of
γ-H2AX, highlighted persistent damages in cells
incubated with Olaparib, B02 or both. For Olaparib,
the remaining γH2AX could be associated with
a continuing production of DSBs from SSBs hitting
the replication fork; for B02, HR being impaired,
a lack of DSB repair is probably involved and explains
the slower decrease in γH2AX level; and for the
combination both production of DSBs and lack of
repair could be implicated. Moreover, cells incubated
with both inhibitors displayed increased levels of p21
mRNAand a higher proportion ofG2 arrested cells as
well as an increased proportion of apoptotic cells over
72 h post-irradiation compared to cells incubated
without inhibitors. It was also highlighted that, for
proton irradiation, serum drastically affects the effect
of Olaparib-B02 combination. This is in agreement
with the fact that radiosensitization using PARPi is
replication dependent [45]. Indeed, DNA synthesis
was faster in the presence of serum, hence inducing
supplementary stalled replication forks in the pre-
sence of Olaparib, followed by DBS formation and
ultimately increased cell death. Finally, if combined
with the effect of B02, the DSBs produced at the
replication forks cannot be repaired by homologous
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recombination leading a further increase in cell death,
i.e. to a synergy between the inhibitors. This was
confirmed in two pancreatic cancer cell lines that
display very different proliferation rate. Indeed,
Olaparib and B02 combination led to a strong
synergy only in the fast cycling KP4 cells while antag-
onism was observed for PANC1 cells. Nonetheless,
a strong radiosensitization was observed for both cell
lines with SER at 37% being as high as 1.6 for PANC1
treated with Olaparib and 1.8 for KP4 treated with
inhibitors combined.
This work demonstrated the benefit of radiation-
induced synthetic lethality, i.e. Olaparib and B02 led
to limited cytotoxic (alone or in combination) but to
an increased cell death when the cells were irradiated
with protons or X-rays. Depending on the prolifera-
tion rate, antagonist, additive or synergistic effects
were observed when combining Olaparib and B02 to
proton irradiation. This type of approach suggests
that the therapeutic window could be expanded as
the enhanced cell killing only happens in the irra-
diated area and depends on a high proliferation rate.
This would be especially the case in tumor with fast
replicating cells in the vicinity of slow or non-
proliferating healthy tissues like in the brain or in
the pancreas.
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